Merck-Moderna vaccine data spur talk of Keytruda-like impact
Merck-Moderna vaccine data spur talk of Keytruda-like impact
Biopharmaceutical company
Merck-Moderna vaccine data spur talk of Keytruda-like impact
Merck’s Moderna-partnered vaccine success clears view of post-Keytruda future
Merck and Sarah Cannon team up for oncology trial efficiency
Merck and Sarah Cannon team up for oncology trial efficiency
Merck, Moderna Personalized mRNA Cancer Therapy Achieves a First for Melanoma
New study supports expanded testing of Merck's Ebola vaccine in response to the ongoing DRC outbreak.
Merck scraps a Phase 2 Alzheimer's asset from partner Neuphoria — Endpoints News coverage of biopharma industry developments.
Merck halts ph. 2 Alzheimer’s trial after underwhelming efficacy — Fierce Biotech coverage of biopharma industry developments.